<DOC>
	<DOCNO>NCT02491892</DOCNO>
	<brief_summary>This study evaluate efficacy safety pertuzumab ( rhuMAb 2C4 ) participant metastatic breast cancer progress standard chemotherapy amenable curative therapy . Those maintain response therapy stable disease end formal study period continue treatment disease progression unacceptable toxicity . Approximately 120 participant enrol .</brief_summary>
	<brief_title>A Study Pertuzumab Participants With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Females least 18 year age Histologicallyconfirmed metastatic breast cancer low HER2 expression least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) Karnofsky performance status least 80 % Disease progression on/after 2 different chemotherapy regimen , include anthracyclinecontaining therapy Left ventricular ejection fraction ( LVEF ) least 50 % Adequate liver function Pleural effusion , ascites , bone lesion manifestation ( ) cancer Pulmonary central nervous system ( CNS ) metastases Chemotherapy , radiotherapy , immunotherapy within 4 week ; hormone therapy within 2 week Day 1 Previous treatment drug target HER2 receptor family Previous treatment corticosteroid cancer therapy History significant cardiac disease Major surgery trauma within 4 week Day 1 Pregnant lactate woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>